• Search
  • Advanced Search
Clin Mol Hepatol > Accepted Articles
Editorial
Besifovir: a viable option for long-term disease control in chronic hepatitis B
Wai-Kay Seto
Department of Medicine and State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China
Correspondence :  Wai-Kay Seto ,
Email: wkseto@hku.hk
Received: March 15, 2025   Accepted: March 20, 2025
TOOLS
METRICS Graph View
  • 0 Crossref
  •  0 Scopus
  • 319 View
  • 18 Download
Related articles

Linvencovir: Paving the way for functional cure in hepatitis B2024 April;30(2)

Comprehensive approach to controlling chronic hepatitis B in China2024 April;30(2)

Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients2023 July;29(3)

Novel biomarkers for the management of chronic hepatitis B2020 July;26(3)

Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?2016 June;22(2)

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 685
TOTAL : 2944659
Close layer